delight over responses of the Johnson & Johnson COVID-19 vaccine. He said, “Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally. We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern”.
Johnson & Johnson Global Head, Mathai Mammen, MD, PhD, at Janssen Research & Development expressed optimism about the company’s vaccine. He said, “Current data for the eight months studied so far show that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time. In addition, we observe a persistent and particularly robust, durable cellular immune response.” Mammen added “With each new dataset, we build on our solid foundation of evidence that our single-shot COVID-19 vaccine plays a critical role in ending the pandemic, which continues to evolve and pose new challenges to global health”.
The data revealed that the Johnson & Johnson single-dose COVID-19 vaccination induced humoral and cellular immune responses that endured for a minimum of eight months, which is the study’s most recent time point. During the emergency times of the pandemic, the vaccination is available for free in many regions and nations. On February 27, it obtained emergency use authorization (EUA) in the United States, and on March 11, it obtained Conditional Marketing Authorization (CMA) from the European Commission.
